Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 2/20 | 0.46 |
| ▸ | BIRC3 | Q13489 | 2/20 | 0.46 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727517 | 1.00 | XIAP (0.46) | XIAPBIRC3BIRC2TSHRHPGD | |
| SCHEMBL31159434 | 0.80 | FABP5 (0.51) | KMT2A | |
| SCHEMBL799703 | 0.80 | FABP5 (0.51) | KMT2A | |
| SCHEMBL3366299 | 0.80 | FABP5 (0.51) | KMT2A | |
| Fluoride SCHEMBL7821537 | 0.79 | FABP5 (0.50) | KMT2A | |
| SCHEMBL13259973 | 0.78 | FABP5 (0.46) | KMT2A | |
| SCHEMBL16371245 | 0.76 | HTT (0.42) | XIAPBIRC3BIRC2TSHRHPGD | |
| SCHEMBL27145258 | 0.76 | HTT (0.42) | XIAPBIRC3BIRC2TSHRHPGD | |
| SCHEMBL28658103 | 0.76 | HTT (0.42) | XIAPBIRC3BIRC2TSHRHPGD | |
| SCHEMBL31370144 | 0.76 | FABP5 (0.49) | ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190688-A1 | Tetrapeptide analogs | TP53, PCNA, HRAS | XIAP 141/4885BIRC3 222/4885BIRC2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.